Novo Nordisk acquires Dicerna Pharmaceuticals, which develops mRNA-based drugs. The company also owns a technology platform to access intracellular disease targets in hepatic and extrahepatic cells and tissues. Novo Nordisk will pay $3.3 billion, or $38.25 per Dicerna share. The deal is scheduled to close in Q4 2021.
Novo Nordisk acquires Dicerna Pharmaceuticals, which develops mRNA-based drugs. The company also owns a technology platform to access intracellular disease targets in hepatic and extrahepatic cells and tissues. Novo Nordisk will pay $3.3 billion, or $38.25 per Dicerna share. The deal is scheduled to close in Q4 2021. 
novonordisk.com
English (US) 